Research programme: pro-inflammatory gene regulators - Amgen

Drug Profile

Research programme: pro-inflammatory gene regulators - Amgen

Alternative Names: NF-kappa-B signal transduction pathway inhibitors research programme - Amgen; Pro-inflammatory gene regulators research programme - Amgen; Research programme: NF-kappa-B signal transduction pathway inhibitors - Amgen

Latest Information Update: 12 Apr 2007

Price : $50

At a glance

  • Originator Amgen
  • Class
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 12 Apr 2007 No development reported - Preclinical for Inflammation in USA (PO)
  • 17 Aug 2004 Tularik has been acquired and merged into Amgen
  • 12 Dec 2003 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top